Long-term cost consequences of community-acquired pneumonia in adults

American Journal of Pharmacy Benefits

Volumn 5, Issue 3, 2013, Pages

  Wasser, Thomas ^a   Yu, Jingbo ^a   Singer, Joseph ^a   Tulsi, Bernard ^a   Sato, Reiko ^b  

^a HEALTHCORE INC   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ADULT; ARTICLE; CHARLSON COMORBIDITY INDEX; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; DATA BASE; DEYO CHARLSON COMORBIDITY INDEX; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HIGH RISK PATIENT; HOSPITAL COST; HUMAN; ICD-9-CM; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHARMACY; RETROSPECTIVE STUDY; RISK ASSESSMENT; THORAX RADIOGRAPHY; UNITED STATES;

EID: 84880130192     PISSN: 19454481     EISSN: 21642494     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Carbon C, Bax RP. Regulating the use of antibiotics in the community. BMJ. 1998;317(7159):663-665.
2. El Moussaoui R, Opmeer BC, de Borgie CA, et al. Long-term symptom recovery and health-related quality of life in patients with mild-to-moderate-severe community-acquired pneumonia. Chest. 2006;130(4):1165-1172.
3. Polverino E, Torres MA. Community-acquired pneumonia. Minerva Anestesiol. 2011;77(2):196-211.
4. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis. 2000;31(2):347-382.
5. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin Ther. 1998;20(4):820-837.
6. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163(7):1730-1754.
7. National Vital Statistics Reports, Vol. 60 No. 4. http://www.cdc.gov/nchs/data/nvsr/nvsr60/nvsr60_04.pdf. Published January 11, 2012. Accessed April 5, 2012.
8. Jackson ML, Neuzil KM, Thompson WW, et al. The burden of community acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis. 2004;39(11):1642-1650.
9. Colice GL, Morley MA, Asche C, Birnbaum HG. Treatment costs of community acquired pneumonia in an employed population. Chest. 2004;125(6):2140-2145.
10. File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010;122(2):130-141.
11. Metlay JP, Fine MJ. Testing strategies in the initial management of patients with community-acquired pneumonia. Ann Intern Med. 2003;138(2):109-118.
12. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(suppl 2): S27-S72.
13. Barlow GD, Lamping DL, Davey PG, Nathwani D. Evaluation of outcomes in community-acquired pneumonia: a guide for patients, physicians, and policymakers. Lancet Infect Dis. 2003;3(8):476-488.
14. Fine MJ, Stone RA, Singer DE, et al. Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study. Arch Intern Med. 1999;159(9):970-980.
15. Marrie TJ. Normal resolution of community-acquired pneumonia. Semin Respir Infect. 1992;7(4):256-270.
16. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Feagan BG. Predictors of symptom resolution in patients with community-acquired pneumonia. Clin Infect Dis. 2000;31(6):1362-1367.
17. Marrie TJ, Beecroft MD, Herman-Gnjidic Z. Resolution of symptoms in patients with community-acquired pneumonia treated on an ambulatory basis. J Infect. 2004;49(4):302-309.
18. Metlay JP, Fine MJ, Schulz R, et al. Measuring symptomatic and functional recovery in patients with community-acquired pneumonia. J Gen Intern Med. 1997;12(7):423-430.
19. Metlay JP, Atlas SJ, Borowsky LH, Singer DE. Time course of symptom resolution in patients with community-acquired pneumonia. Respir Med. 1998; 92(9):1137-1142.
20. Brandenburg JA, Marrie TJ, Coley CM, et al. Clinical presentation, processes and outcomes of care for patients with pneumococcal pneumonia. J Gen Intern Med. 2000;15(9):638-646.
21. Lettinga KD, Verbon A, Nieuwkerk PT, et al. Health-related quality of life and posttraumatic stress disorder among survivors of an outbreak of Legionnaires disease. Clin Infect Dis. 2002;35(1):11-17.
22. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). Morb Mortal Wkly Rep. 2010;59(34):1102-1106.
23. Weycker D, Strutton D, Edelsberg J, Sato R, Jackson LA. Clinical and economic burden of pneumococcal disease in older US adults. Vaccine. 2010;28(31): 4955-4960.
24. Sprent P. Applied Non Parametric Statistical Methods. London, UK: Chapman and Hall; 1989.
25. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
26. Bounthavong M, Hsu DI, Okamoto MP. Cost-effectiveness analysis of linezolid vs. vancomycin in treating methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic model. Int J Clin Pract. 2009;63(3):376-386.